BIO-TECHNE CORP shareholders Q2 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Asset Management One Co., Ltd. 15,861$5,498,0000.03%
Stonebridge Capital Advisors LLC 629$218,0000.03%
Russell Investments Group, Ltd. 36,311$12,591,0000.03%
TWO SIGMA INVESTMENTS, LP 22,702$7,869,0000.03%
STATE OF MICHIGAN RETIREMENT SYSTEM 10,611$3,678,0000.02%
Achmea Investment Management B.V. 2,257$782,0000.02%
KB FINANCIAL PARTNERS, LLC 204$71,0000.02%
HRT FINANCIAL LP 6,646$2,303,0000.02%
Desjardins Global Asset Management Inc. 547$189,0000.02%
Sumitomo Mitsui DS Asset Management Company, Ltd 2,965$1,028,0000.02%
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 77,933$27,015,0000.02%
BOK Financial Private Wealth, Inc. 800$277,0000.02%
Avalon Investment & Advisory 2,500$867,0000.02%
DEUTSCHE BANK AG\ 122,255$42,378,0000.02%
SFMG, LLC 603$209,0000.02%
UBS ASSET MANAGEMENT AMERICAS LLC 134,619$46,664,329,0000.02%
MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC 5,345$1,853,0000.02%
PICTET ASSET MANAGEMENT SA 49,097$17,019,0000.02%
Robeco Institutional Asset Management B.V. 22,541$7,816,0000.02%
Louisiana State Employees Retirement System 2,500$876,0000.02%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.